Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer
Summary
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the tumor and improve survival of the patients.
General Information
NCT#: NCT02705196
Study ID: LOKON001
Trial Phase: Phase I/II
Trial Sponsor: Lokon Pharma AB
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, LOAd703 Injection, Atezolizumab